Dose, Safety, Tolerability, and Immunogenicity of an HIV-1 Vaccine, VRC-HIVRGP096-00-VP, With Alum in Healthy Adults

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

16 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-03-07

Study Completion Date

2020-06-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Background:

HIV stands for human immunodeficiency virus, which is the virus that causes AIDS. There is currently no licensed vaccine to prevent HIV infection. Researchers want to test a vaccine called Trimer 4571 for the first time. It was made at the National Institutes of Health (NIH) and contains no HIV. The vaccine is mixed with a substance called alum and injected in the arm. Alum is included to boost the body's immune response to the vaccine. It has been used in licensed vaccines for over 60 years and has been found to be safe.

Objectives:

To see if the vaccine Trimer 4571 is safe, well-tolerated, and to study immune responses to it.

Eligibility:

Healthy adults ages 18-50 years

Design:

Participants were screened with a physical exam and blood tests. They agreed to not become pregnant and to avoid behavior that would put them at high-risk for HIV infection during the study.

Participants had about 15 study visits over about 9 months.

The first 6 participants received a low dose of the vaccine mixed with alum.

Once the low dose was deemed safe, 10 new participants were allocated to receive a higher dose.

All participants were randomly assigned to get the vaccine by injection in a muscle or under the skin.

All participants received a total of 3 vaccine injections over 20 weeks. Each visit where participants received the vaccine lasted about 5 hours. Participants were watched after each injection. Participants who were able to get pregnant would have a pregnancy test before each injection.

Participants received a thermometer and recorded their temperature and symptoms every day for 1 week after each injection. The injection site was checked for redness, swelling, or bruising.

At follow-up visits, participants had blood drawn and checked for health changes or problems. Follow up visits lasted about 1-2 hours.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

HIV-1 Vaccine Booster in Previously Immunized Uninfected Adult Volunteers

NCT00102089

Healthy HIV Infections

COMPLETED PHASE1

Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy

NCT04985760

HIV Infections

COMPLETED PHASE1

Safety and Immunogenicity of Ad4-HIV Envelope Vaccine Vectors in Healthy Volunteers

NCT03878121

Healthy Volunteer

RECRUITING PHASE1

Safety of and Immune Response to an HIV-1 DNA Vaccine (VRC HIVDNA009-00-VP) in HIV Uninfected Adults

NCT00071851

HIV Infections

COMPLETED PHASE1/PHASE2

Phase 1 Safety Study of Two Experimental HIV Vaccines

NCT00479999

AIDS Vaccines HIV Infections HIV-1

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Design:

This is a Phase I, open-label, dose escalation study to evaluate the dose, safety, tolerability, and immunogenicity of VRC-HIVRGP096-00-VP (Trimer 4571) with aluminum hydroxide suspension (alum) as adjuvant in a three-injection regimen. The hypotheses were that the vaccine will be safe and tolerable and will induce detectable immune responses. The primary objective was to evaluate the safety and tolerability of the investigational vaccine at three doses administered with alum. Secondary objectives were to evaluate humoral and cellular immunogenicity of the investigational vaccine regimens.

Study Product:

VRC-HIVRGP096-00-VP (Trimer 4571) was developed by the Vaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases (NIAID). The soluble HIV-1 envelope product consists of an HIV-1 envelope (Env) trimer variant, derived from clade A, strain BG505, with stabilizing mutations and engineered disulfide bonds, specifically recognized by broadly neutralizing antibodies and resists gp120 conformational change caused by CD4 binding. Injections were administered intramuscularly (IM) and subcutaneously (SC) in a 1 mL volume by needle and syringe. The product was provided at a 500 mcg/mL concentration in 3 mL glass vials filled to 1.2 +/- 0.10 mL. Adjuvant is an aluminum hydroxide suspension (alum) provided in a sterile, pyrogen-free suspension at a concentration of 5 mg/mL in 3 mL glass vials filled to 0.7 +/- 0.10 mL.

Participants:

Healthy adults ages 18 to 50.

Study Plan:

Participants received VRC-HIVRGP096-00-VP at doses of 100 mcg or 500 mcg, both with 500 mcg alum field mixed, administered via IM or SC injections. A dose escalation evaluation occurred to ensure the safety data supported proceeding to the higher dose. Participants were evaluated for safety and immune responses through blood collection at specified timepoints throughout the study.

The study schema is below:

\--------------------

Group 1: Participants = 3; Route = IM; Dose (mcg) = 100; Day\*\* 0, Week\*\* 8, Week\*\* 20

Group 2: Participants = 3; Route = SC; Dose (mcg) = 100; Day\*\* 0, Week\*\* 8, Week\*\* 20

Group 3: Participants = 5; Route = IM; Dose (mcg) = 500; Day\*\* 0, Week\*\* 8, Week\*\* 20

Group 4: Participants = 5; Route = SC; Dose (mcg) = 500; Day\*\* 0, Week\*\* 8, Week\*\* 20

Total = 16 Participants

\*\*500 mcg of alum was mixed with Trimer 4571 for all groups

Duration:

Participants were followed for 40 weeks.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Human Immunodeficiency Virus Prevention Human Immunodeficiency Virus (HIV)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1: Trimer 4571 (100 mcg) IM with alum

Trimer 4571 injections (100 mcg), with 500 mcg of alum field mixed, administered intramuscularly (IM) in a 1 mL volume by Needle/Syringe on Day 0, Week 8, and Week 20

Group Type EXPERIMENTAL

VRC-HIVRGP096-00-VP

Intervention Type BIOLOGICAL

Trimer 4571 drug product is an investigational HIV vaccine which mimics the native HIV-1 envelope complex. This soluble HIV-1 envelope product consists of an HIV-1 envelope (Env) trimer variant, derived from clade A, strain BG505, with stabilizing mutations and engineered disulfide bonds, specifically recognized by broadly neutralizing antibodies and resists gp120 conformational change caused by CD4 binding.

Alum Adjuvant

Intervention Type OTHER

Adjuvant is an aluminum hydroxide suspension (alum) mixed with Trimer 4571 to improve the immune response to the investigational vaccine.

Group 2: Trimer 4571 (100 mcg) SC with alum

Trimer 4571 injections (100 mcg), with 500 mcg of alum field mixed, administered subcutaneously (SC) in a 1 mL volume by Needle/Syringe on Day 0, Week 8, and Week 20

Group Type EXPERIMENTAL

VRC-HIVRGP096-00-VP

Intervention Type BIOLOGICAL

Trimer 4571 drug product is an investigational HIV vaccine which mimics the native HIV-1 envelope complex. This soluble HIV-1 envelope product consists of an HIV-1 envelope (Env) trimer variant, derived from clade A, strain BG505, with stabilizing mutations and engineered disulfide bonds, specifically recognized by broadly neutralizing antibodies and resists gp120 conformational change caused by CD4 binding.

Alum Adjuvant

Intervention Type OTHER

Adjuvant is an aluminum hydroxide suspension (alum) mixed with Trimer 4571 to improve the immune response to the investigational vaccine.

Group 3: Trimer 4571 (500 mcg) IM with alum

Trimer 4571 injections (500 mcg), with 500 mcg of alum field mixed, administered intramuscularly (IM) in a 1 mL volume by Needle/Syringe on Day 0, Week 8, and Week 20

Group Type EXPERIMENTAL

VRC-HIVRGP096-00-VP

Intervention Type BIOLOGICAL

Trimer 4571 drug product is an investigational HIV vaccine which mimics the native HIV-1 envelope complex. This soluble HIV-1 envelope product consists of an HIV-1 envelope (Env) trimer variant, derived from clade A, strain BG505, with stabilizing mutations and engineered disulfide bonds, specifically recognized by broadly neutralizing antibodies and resists gp120 conformational change caused by CD4 binding.

Alum Adjuvant

Intervention Type OTHER

Adjuvant is an aluminum hydroxide suspension (alum) mixed with Trimer 4571 to improve the immune response to the investigational vaccine.

Group 4: Trimer 4571 (500 mcg) SC with alum

Trimer 4571 injections (500 mcg), with 500 mcg of alum field mixed, administered subcutaneously (SC) in a 1 mL volume by Needle/Syringe on Day 0, Week 8, and Week 20

Group Type EXPERIMENTAL

VRC-HIVRGP096-00-VP

Intervention Type BIOLOGICAL

Trimer 4571 drug product is an investigational HIV vaccine which mimics the native HIV-1 envelope complex. This soluble HIV-1 envelope product consists of an HIV-1 envelope (Env) trimer variant, derived from clade A, strain BG505, with stabilizing mutations and engineered disulfide bonds, specifically recognized by broadly neutralizing antibodies and resists gp120 conformational change caused by CD4 binding.

Alum Adjuvant

Intervention Type OTHER

Adjuvant is an aluminum hydroxide suspension (alum) mixed with Trimer 4571 to improve the immune response to the investigational vaccine.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

VRC-HIVRGP096-00-VP

Trimer 4571 drug product is an investigational HIV vaccine which mimics the native HIV-1 envelope complex. This soluble HIV-1 envelope product consists of an HIV-1 envelope (Env) trimer variant, derived from clade A, strain BG505, with stabilizing mutations and engineered disulfide bonds, specifically recognized by broadly neutralizing antibodies and resists gp120 conformational change caused by CD4 binding.

Intervention Type BIOLOGICAL

Alum Adjuvant

Adjuvant is an aluminum hydroxide suspension (alum) mixed with Trimer 4571 to improve the immune response to the investigational vaccine.

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Trimer 4571 Aluminum Hydroxide Suspension Alum

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

A participant must have met all of the following criteria:

1. Able and willing to complete the informed consent process.
2. 18-50 years old, inclusive, on day of enrollment.
3. Available for clinic follow-up through the last study visit.
4. Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process.
5. Willing to donate blood for sample storage to be used for future research.
6. In good general health without clinically significant medical history.
7. Physical examination and laboratory results without clinically significant findings.
8. Body Mass Index (BMI) less than or equal to 40.
9. Assessed as low risk for human immunodeficiency virus (HIV) acquisition by agreeing to discuss HIV infection risks, agreeing to risk reduction counseling, and agreeing to avoid behavior associated with high risk of HIV exposure through the end of study.
10. Screening laboratory values within 56 days prior to enrollment that met the following criteria:

* Hemoglobin within the institutional normal limits
* White blood cell (WBC) count between 2,500-12,000/mm\^3
* WBC differential absolute cell counts either within institutional normal range or accompanied by site Principal Investigator (PI) or Associate Investigator (AI) approval, except neutrophils and lymphocytes must specifically be within the range of greater than or equal to 0.75 x the lower limit of normal (LLN) and lees than or equal to 1.25 x the upper limit of normal (ULN) for neutrophil and lymphocyte absolute counts
* Platelets = 125,000-500,000/m\^3
* Alanine aminotransferase (ALT) less than or equal to 1.25 x ULN based on the institutional normal range
* Serum creatinine less than or equal to 1.1 x ULN based on the institutional normal range
* Negative for HIV infection by an FDA approved method of detection

Woman-specific (if presumed to be of childbearing potential):
11. Agrees to use effective means of birth control from at least 21 days prior to enrollment through the end of the study.
12. Negative beta-HCG (human chorionic gonadotropin) pregnancy test (urine or serum) on day of enrollment.

Exclusion Criteria

A participant was excluded if one or more of the following conditions apply:

Woman-specific:

1. Breast-feeding or planning to become pregnant through the end of study.

Participant has received any of the following:
2. An investigational HIV vaccine.
3. Systemic glucocorticoid use equal or greater than prednisone 20mg/day within 4 weeks prior to enrollment, or other medication use likely to impair vaccine response.
4. Blood products within 16 weeks prior to enrollment.
5. Live attenuated vaccines within 4 weeks prior to enrollment.
6. Inactivated vaccines within 2 weeks prior to enrollment.
7. Investigational research agents within 4 weeks prior to enrollment.
8. Current allergen immunotherapy with antigen injections, unless on maintenance schedule.
9. Current anti-tuberculosis (TB) prophylaxis or therapy.

Participant had any of the following:
10. Serious reactions to vaccines that preclude receipt of study injections as determined by the principal investigator or designee.
11. Hereditary angioedema, acquired angioedema, or idiopathic forms of angioedema.
12. Hypertension that is not well controlled.
13. Evidence of significant autoimmune disease or immunodeficiency.
14. Idiopathic urticaria within the past year.
15. Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws.
16. Seizure disorder other than: 1) febrile seizures, 2) seizures secondary to alcohol withdrawal more than 3 years ago, or 3) seizures that have not required treatment within the last 3 years.
17. Asplenia or functional asplenia.
18. Any other chronic or clinically significant condition that in the opinion of the investigator would jeopardize the safety or rights of the study subject including but not limited to: diabetes mellitus type I, chronic hepatitis; OR clinically significant forms of: drug or alcohol abuse, asthma, psychiatric disorders, heart disease, or cancer.

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes